F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roc

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase

Related Keywords

Japan , Canada , United States , Switzerland , America , Sabine Borngr , Nathalie Altermatt , Bruno Eschli , Gerard Tobin , Loren Kalm , Birgit Masjost , Levi Garraway , Drug Administration , World Health Organization , Roche Group , Roche Group Media Relations , Genentech , Head Of Global Product Development , European Commission , Health Canada , European Medicines Agency , Medicinal Products , Human Use , Chief Medical Officer , Global Product , New England Journal , Fixed Duration Columvi , Biologics License Application , Dow Jones Sustainability Indices , Chugai Pharmaceutical , World Health , Cancer Incidence , Refractory Diffuse Largeb Cell , Hoffmann , Oche , Thmp , Ecommends , Approval , Ixed , Uration , Columvi , Glofitamab , People , Relapsed , Refractory , Diffuse , Barge , Fell , Lymphoma ,